Summit Global Investments Acquires New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

Summit Global Investments bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,453 shares of the company’s stock, valued at approximately $541,000.

Several other institutional investors have also recently bought and sold shares of the business. Entropy Technologies LP bought a new stake in shares of Krystal Biotech during the 4th quarter valued at approximately $548,000. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech during the third quarter worth $1,893,000. Swiss National Bank increased its holdings in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after acquiring an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. lifted its stake in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $194.44 on Tuesday. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The firm’s fifty day moving average is $167.55 and its 200-day moving average is $173.62. The firm has a market cap of $5.60 billion, a P/E ratio of 65.03 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus price target of $220.00.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).